Mundipharma signs a deal with Grü­nen­thal

BioSpectrum (Asia) - - Company News -

Mor­photek Inc., a sub­sidiary of Ei­sai Inc., has li­censed its eribu­lin-linker pay­load to Bliss Bio­phar­ma­ceu­ti­cal Co., Ltd. (Blis­sBio) of China. The li­cens­ing agree­ment grants Blis­sBio the ex­clu­sive right to use the eribu­lin-linker pay­load to de­velop a ther­a­peu­tic an­ti­body drug con­ju­gates (ADCs) against an undis­closed on­col­ogy tar­get for the China mar­ket. The li­cens­ing agree­ment in­cludes an up­front pay­ment, mile­stones and sales roy­alty pay­ments, which are undis­closed. Blis­sBio has an ex­clu­siv­ity op­tion to ex­pand the ter­ri­tory beyond China to the global mar­ket and to de­velop ther­a­peu­tic ADCs to two additional undis­closed on­col­ogy tar­gets.

Mor­photek’s ADC Ser­vices of­fer third par­ties the op­por­tu­nity to license the pro­pri­etary eribu­lin-linker pay­load to de­velop in­ves­ti­ga­tional ADCs us­ing ei­ther Mor­photek’s REsidueSPE­cific Con­ju­ga­tion Tech­nol­ogy (RE­SPECT) or an al­ter­na­tive ap­proach to con­ju­ga­tion.

The eribu­lin-linker pay­load con­sists of a cy­to­toxic agent, eribu­lin, mod­i­fied by a chem­i­cal linker to fa­cil­i­tate op­ti­mal con­ju­ga­tion. Eribu­lin’s an­ti­tu­mor ac­tiv­ity is me­di­ated by the in­hi­bi­tion of mi­cro­tubule elon­ga­tion and mi­totic spin­dle for­ma­tion, re­sult­ing in apop­to­sis. Eribu­lin me­sy­late, mar­keted as Halaven, is ap­proved in the US for the treat­ment of pa­tients with metastatic breast can­cer who have pre­vi­ously re­ceived at least two chemother­a­peu­tic reg­i­mens for metastatic dis­ease, in­clud­ing an an­thra­cy­cline and a tax­ane in ei­ther the ad­ju­vant or metastatic set­ting.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.